Jazz Pharmaceuticals
在场
是其中之一......
Jazz Pharmaceuticals 是一家在股票代码 JAZZ (US) 下上市的公司。
Jazz Pharmaceuticals 在 3 个国家有直接业务。
高管
查看带有其 38 名主要高管的组织结构图
Jazz Pharmaceuticals 搜索最多的简介
- Bruce Cozadd, Chairman and Chief Executive Officer (retiring)
- Kenneth O'Keefe, Director
- Seamus Mulligan, Director
高管在Jazz Pharmaceuticals变化
- Bruce Cozadd是 Chairman and Chief Executive Officer，他即将退休。 (新闻发布的2024十二月18号).
- Laura Hamill已作为Director加入公司 (新闻发布的2024七月28号).
- Samantha Pearce 曾任 Senior Vice President, Europe and International, 将于 20248月1 升职为 Chief Commercial Officer (新闻发布的2024七月11号).
创建提醒
跟踪 Jazz Pharmaceuticals 的高管变动
药店
Jazz Pharmaceuticals 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Jazz Pharmaceuticals 的最新新闻稿
- Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022 | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics | Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist | Jazz Pharmaceuticals plc
- View more press releases Close
通过电子邮件
